PT3481964T - Biomarcadores para doença inflamatória intestinal - Google Patents

Biomarcadores para doença inflamatória intestinal

Info

Publication number
PT3481964T
PT3481964T PT177682200T PT17768220T PT3481964T PT 3481964 T PT3481964 T PT 3481964T PT 177682200 T PT177682200 T PT 177682200T PT 17768220 T PT17768220 T PT 17768220T PT 3481964 T PT3481964 T PT 3481964T
Authority
PT
Portugal
Prior art keywords
biomarkers
inflammatory bowel
bowel disease
disease
inflammatory
Prior art date
Application number
PT177682200T
Other languages
English (en)
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of PT3481964T publication Critical patent/PT3481964T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
PT177682200T 2016-07-05 2017-07-05 Biomarcadores para doença inflamatória intestinal PT3481964T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1611738.4A GB201611738D0 (en) 2016-07-05 2016-07-05 Biomarkers for inflammatory bowel disease

Publications (1)

Publication Number Publication Date
PT3481964T true PT3481964T (pt) 2022-02-17

Family

ID=56891052

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177682200T PT3481964T (pt) 2016-07-05 2017-07-05 Biomarcadores para doença inflamatória intestinal

Country Status (15)

Country Link
US (3) US11041206B2 (pt)
EP (1) EP3481964B1 (pt)
JP (2) JP7111630B2 (pt)
KR (1) KR102352847B1 (pt)
CN (1) CN109477145B (pt)
AU (1) AU2017293417B2 (pt)
CA (1) CA3029912A1 (pt)
DK (1) DK3481964T3 (pt)
ES (1) ES2906192T3 (pt)
GB (1) GB201611738D0 (pt)
HU (1) HUE058197T2 (pt)
LT (1) LT3481964T (pt)
PL (1) PL3481964T3 (pt)
PT (1) PT3481964T (pt)
WO (1) WO2018007872A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10515408B2 (en) 2003-08-13 2019-12-24 Bgc Partners, Inc. Systems and methods for bid/offer liquidity spread trading
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
GB2611267B (en) 2018-10-18 2023-06-28 Smith & Nephew Tissue treatment device
GB201817052D0 (en) 2018-10-19 2018-12-05 Smith & Nephew Tissue treatment device
CN110400603A (zh) * 2019-07-23 2019-11-01 中国石油大学(华东) 基于格局加权的ibd矩阵计算方法
GB201912518D0 (en) 2019-08-30 2019-10-16 Cambridge Entpr Ltd Inflammatory disease prognostics
GB202005867D0 (en) 2020-04-22 2020-06-03 Smith & Nephew Tissue treatment device
GB202100527D0 (en) 2021-01-15 2021-03-03 Smith & Nephew Systems and methods for managing operation of wound dressings or wound treatment devices
BR112023018330A2 (pt) * 2021-03-12 2023-12-05 Janssen Biotech Inc Métodos para predição de resposta ao tratamento em colite ulcerativa
CN114517228A (zh) * 2021-12-31 2022-05-20 青岛锐翌精准医学检验有限公司 炎症性肠病标志基因及其应用
CN114645088B (zh) * 2022-04-22 2023-12-15 广东省人民医院 克罗恩病进展风险相关评估基因集、试剂盒、应用和系统

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412301D0 (en) 2004-06-02 2004-07-07 Diagenic As Product and method
AU2006254971A1 (en) * 2005-06-06 2006-12-14 Wyeth Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
GB0610949D0 (en) * 2006-06-02 2006-07-12 Glaxosmithkline Biolog Sa Method
JP2011509071A (ja) * 2007-11-29 2011-03-24 ジェネンテック, インコーポレイテッド 炎症性腸疾患のための遺伝子発現マーカー
US20100222262A1 (en) * 2008-04-02 2010-09-02 Metaproteomics, Llc Substituted 1, 3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
DK2389582T3 (en) * 2009-01-20 2016-07-18 Cambridge Entpr Ltd Methods for prognosis of the risk of autoimmune diseases
EP2419532A1 (en) * 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
EP2272977A1 (en) 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
AU2011237669B2 (en) * 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
SG194710A1 (en) 2011-05-10 2013-12-30 Nestec Sa Methods of disease activity profiling for personalized therapy management
KR20140097336A (ko) * 2011-11-23 2014-08-06 암젠 인크 인터페론 감마에 대한 항체를 이용한 치료 방법
US20150133469A1 (en) 2012-03-13 2015-05-14 Baylor Research Institute Early detection of tuberculosis treatment response
WO2014054013A1 (en) 2012-10-05 2014-04-10 Nestec S.A. Methods for predicting and monitoring mucosal healing
US20150315643A1 (en) 2012-12-13 2015-11-05 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
KR20150139537A (ko) * 2013-03-15 2015-12-11 더 브로드 인스티튜트, 인코퍼레이티드 수지상 세포의 반응 유전자 발현, 물질의 조성물 및 이의 사용 방법
WO2015120382A1 (en) * 2014-02-07 2015-08-13 The Johns Hopkins University Predicting response to epigenetic drug therapy
CN113604543A (zh) * 2014-03-27 2021-11-05 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2016066288A1 (en) 2014-10-28 2016-05-06 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for inflammatory bowel disease
EP3262193A2 (en) * 2015-02-26 2018-01-03 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
JP2018512876A (ja) 2015-04-22 2018-05-24 ミナ セラピューティクス リミテッド saRNA組成物および使用方法
US20170003277A1 (en) * 2015-07-01 2017-01-05 Michael Hayden Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease

Also Published As

Publication number Publication date
US10640829B2 (en) 2020-05-05
GB201611738D0 (en) 2016-08-17
JP2020198884A (ja) 2020-12-17
EP3481964B1 (en) 2021-12-29
NZ750396A (en) 2020-12-18
WO2018007872A9 (en) 2018-03-15
KR20190025637A (ko) 2019-03-11
US20180010187A1 (en) 2018-01-11
LT3481964T (lt) 2022-04-11
AU2017293417A1 (en) 2019-02-21
HUE058197T2 (hu) 2022-07-28
US10202651B2 (en) 2019-02-12
CN109477145B (zh) 2021-04-09
US20180010189A1 (en) 2018-01-11
CN109477145A (zh) 2019-03-15
ES2906192T3 (es) 2022-04-13
CA3029912A1 (en) 2018-01-11
KR102352847B1 (ko) 2022-01-17
EP3481964A1 (en) 2019-05-15
AU2017293417B2 (en) 2019-11-14
US20190032140A1 (en) 2019-01-31
JP2019527039A (ja) 2019-09-26
DK3481964T3 (da) 2022-02-07
PL3481964T3 (pl) 2022-04-11
US11041206B2 (en) 2021-06-22
JP7111630B2 (ja) 2022-08-02
WO2018007872A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
PL3481964T3 (pl) Biomarkery nieswoistego zapalenia jelita
IL276516A (en) Methods for diagnosing and treating inflammatory bowel disease
EP3201622A4 (en) Markers for inflammatory bowel disease
GB2566681B (en) Biomarker
GB201401603D0 (en) Biomarkers
GB201420908D0 (en) Biomarkers
SG10202007262PA (en) Copanlisib biomarkers
SG10202007322PA (en) Copanlisib biomarkers
EP3284830A4 (en) Biomarker for mental disease
SG11201706686YA (en) Methods for determining resist deformation
GB201614455D0 (en) Biomarkers
HK1251299A1 (zh) 腎病的病態生物標誌物
DK3198034T3 (da) Biomarkører for cervixcancer
ZA202001821B (en) Biomarker
SG10201800570RA (en) Biomarkers for assessing hiv
GB201710858D0 (en) Biomarker
HK1250257A1 (zh) 用於前列腺疾病的生物標記物組合
GB201500729D0 (en) Novel Biomarkers
GB201700439D0 (en) Methods for assessing vaginal atrophy
GB201512133D0 (en) Biomarkers
LU92499B1 (en) Mirna 320a as biomarker for inflammatory bowel disease
ZA201700644B (en) Maize biomarkers for disease resistance
GB201707113D0 (en) Biomarker
GB201613912D0 (en) Predictive biomarker
GB201521446D0 (en) Biomarker